SAN DIEGO, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities who purchased stock pursuant to and/or traceable to Metagenomi Inc.'s (NASDAQ: MGX) registration statement for the initial public offering (IPO) held between February 9 and 13, 2024. Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. For more information, ...

Core Viewpoint - A class action lawsuit has been filed against Metagenomi, Inc. for alleged violations of federal securities laws related to misleading statements made during its IPO [1][4]. Group 1: Lawsuit Details - The Schall Law Firm is representing investors who purchased Metagenomi's securities during its IPO on February 9, 2024, and encourages them to contact the firm before November 25, 2024 [2]. - The lawsuit claims that Metagenomi made false and misleading statements regarding its business relationship with Moderna, which was based on a Strategic Collaboration and License Agreement from October 29, 2021 [4]. Group 2: Impact on Investors - Following the announcement of the termination of the collaboration with Moderna, investors suffered damages as the truth about Metagenomi's misleading public statements was revealed [4].

NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Metagenomi, Inc. ("Metagenomi" or "the Company") (NASDAQ: MGX) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Metagenomi ...

NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the "Class") who purchased or acquired the stock of Metagenomi, Inc. ("Metagenomi" or the "Company") (NASDAQ: MGX) pursuant and/or traceable to Metagenomi's registration statement for the initial public offering held between February 9 and 13, 2024. For more information, submit a form at Metagenomi, Inc. Shareholder Class Action Lawsuit, email I ...

NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all persons or entities who purchased the securities of Metagenomi Inc. ("Metagenomi" or the "Company") (NASDAQ: MGX) between February 9, 2024 and May 1, 2024, both dates inclusive (the "Class Period"). The Complaint alleges that Metagenomi introduced itself to investors during its initi ...

NEW YORK, Sept. 26, 2024 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired stock of Metagenomi, Inc. ("Metagenomi" or the "Company") (NASDAQ: MGX) pursuant and/or traceable to Metagenomi's registration statement for the initial public offering held between February 9 and 13, 2024. You are hereby notified that the class action lawsuit Kevin Vreeland v. Metagenomi, Inc., et al. (Case No. 3:24-cv06765) has been ...

Twelve-month durability data from Metagenomi's ongoing nonhuman primate (NHP) study in hemophilia A remains generally consistent with data previously released at 4.5 months NHPs remain healthy and exhibit normal weight gain; treatment is generally well tolerated Program on track for IND filing in 2026 Company to host conference call with management and Dr. Glenn Pierce, international thought leader in hemophilia A EMERYVILLE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a preci ...

AI-generated, compact SMART nucleases demonstrated robust genome editing activity in vitro in mammalian cells at multiple therapeutically relevant loci Compact SMART genome editing tools that fit within delivery technologies constrained by cargo size may enable broad disease targeting EMERYVILLE, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, ...

EMERYVILLE, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced that it will present during the following upcoming investor conferences: Wells Fargo Healthcare Conference, Everett, Massachusetts Fireside chat on Wednesday, September 4, 2024, 11:00 AM - 11:35 AM ET with Brian Thomas, CEO, Dr. Sarah Noonberg, CMO, and Alan Brooks, SV ...

Exhibit 99.1 ·Jl• Metagenomi Metagenomi Reports Business Updates and Second Quarter 2024 Financial Results Declared development candidate MGX-001 for the treatment of hemophilia A; plans to present 12-month NHP durability study data in September 2024 All Wave 1 Ionis collaboration programs advancing in lead optimization, unlocking potential for multiple development candidate nominations in 2025 Achieved milestone from partner Affini-T related to Metagenomi licensed technology Well capitalized with $299.9M i ...